When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios (or "P/S") above 1.2x, you may consider Owens & Minor, Inc. (NYSE:OMI) as an attractive investment with its 0.1x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.
How Has Owens & Minor Performed Recently?
Owens & Minor could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.
Keen to find out how analysts think Owens & Minor's future stacks up against the industry? In that case, our free report is a great place to start.
What Are Revenue Growth Metrics Telling Us About The Low P/S?
There's an inherent assumption that a company should underperform the industry for P/S ratios like Owens & Minor's to be considered reasonable.
Taking a look back first, we see that the company managed to grow revenues by a handy 3.9% last year. The solid recent performance means it was also able to grow revenue by 12% in total over the last three years. Therefore, it's fair to say the revenue growth recently has been respectable for the company.
Looking ahead now, revenue is anticipated to climb by 4.9% each year during the coming three years according to the six analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 7.5% per year, which is noticeably more attractive.
With this information, we can see why Owens & Minor is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.
What Does Owens & Minor's P/S Mean For Investors?
Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
As we suspected, our examination of Owens & Minor's analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. The company will need a change of fortune to justify the P/S rising higher in the future.
You should always think about risks. Case in point, we've spotted 1 warning sign for Owens & Minor you should be aware of.
It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
当超过半数在美国医疗保健行业运营的公司的市销率高于1.2倍时,你可以考虑Owens & Minor, Inc. (纽交所:OMI)的0.1倍市销率作为一个具有吸引力的投资选项。然而,我们需要深入挖掘一下,以判断降低买卖比率的合理性。
近期Owens & Minor 的表现
Owens & Minor 最近营收增长落后于其他大部分公司,可能市场预计当前营收增长趋势将持续下去,这使得买卖比率被压制。如果情况是这样,那么现有股东可能会对股票未来方向感到沮丧。
想知道分析师们如何看待Owens & Minor 的未来与行业的差异吗?那么,我们的免费报告是一个很好的起点。